|Day Low/High||39.87 / 40.28|
|52 Wk Low/High||38.14 / 50.65|
A steeper fall might cause both buyers and sellers to re-think potential deals, but so far that doesn't seem to be the case yet.
What is the strike price, and/or what the expiration date might be on such plunge protection?
A week after unveiling an $11.6-billion deal for Bioverativ, Sanofi said it was spending another $4.8 billion to acquire Belgian biotech firm Ablynx.
U.S. stock futures trade lower, Donald Trump's national security advisers look at building a 5G network, and France's Sanofi buys Belgian biotech Ablynx.
As the Trump administration reportedly considers government controlled 5G, investors prepare for a hectic week of earnings.
Consumer spending should be more than solid given wage increases.
Here's what you need to know now for Monday, Jan. 22.
With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.
A flurry of high-priced merger-and-acquisition activity explains the move in Allergan.
Stocks hit fresh records on Monday after a deal is reached to end the three-day government shutdown.
Stocks turn higher on Monday, as investors watch for the impact of a federal government shutdown that entered its third day.
Another New England Patriots win in the Super Bowl could mean bad things for the stock market. What government shutdown?
The stock market's impressive start to the year is at risk as the government shutdown enters day three. Meanwhile, a series of healthcare deals captivates Wall Street's attention.
So what does a government shutdown mean for today's trading? Here's what you need to know before Monday's opening bell.
U.S. stock futures suggest Wall Street will open lower on Monday, as investors watch for the impact of a federal government shutdown that has extended into its third day.
France's Sanofi could end its long search for a biotech deal after striking an $11.6 billion offer for Massachusetts-based Bioverativ, a maker of hemophilia treatments.
Helped by a relaxed regulatory environment, telco giants could pursue M&A to build and prioritize their own content libraries.
Sanofi has launched two new late-stage clinical studies to determine if an investigational biologic called isatuximab, when used in combination with other commonly used cancer treatments, might be an effective treatment...
Two large real-world analyses compared adults with type 2 diabetes who were switched to Toujeo (insulin glargine injection 300 Units/mL) to those switched to insulin degludec
Some French companies will get a temporary windfall, but others will need to pay more tax.
Tesla and General Motors are among this week's names showing reversal patterns.
The French drugmaker's under pressure diabetes treatments slid less than expected but sales of its growing multiple sclerosis products underwhelmed.
Investors keep an eye on another busy slate of earnings.
Uncertainty in Washington, D.C., a healthcare sector in selloff mode and a big deals day on Wall Street sent U.S. equities lower to begin the week.
Stocks dig further into the red on Monday, Oct. 30, as investors weigh how a proposed phase-in corporate tax rate cut might impact U.S. companies.
Stocks are mixed on Monday as Mueller's Russia investigation takes its first concrete steps.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.